STOCKS TELEGRAPH

Tag: NAOV STOCK PRICE

  • Surge In NanoVibronix (NAOV) Shares Sparks Market Curiosity

    Surge In NanoVibronix (NAOV) Shares Sparks Market Curiosity

    The stock market is seeing a spectacular surge in NanoVibronix, Inc. (NASDAQ: NAOV) shares, which were rising 381.88% to $14.17 as of the most recent check today. The spike seems to be driven by recent encouraging developments about NanoVibronix’s core medical product, UroShield, and its expansion of distribution in Australia, even if there was no immediate breaking news.

    Extended and Renewing Contract

    NanoVibronix announced earlier this month that it has extended and renewed its exclusive three-year distribution arrangement with Dukehill Healthcare Pty Ltd, a Queensland-based company. All Australian states are now covered by Dukehill’s distribution rights, which were formerly restricted to Queensland and New South Wales.

    This move comes after a noticeable rise in orders and questions from medical facilities, especially in Victoria and South Australia, indicating increased interest in UroShield’s potential in clinical settings.

    Increasing Trust in UroShield’s Performance

    The enlarged agreement follows an independent research that demonstrated UroShield’s efficacy in reducing catheter-associated problems and enhancing patient outcomes. The market’s favorable reaction is probably due in part to the research, which has reaffirmed NanoVibronix’s dedication to extending access to its technology.

    NAOV stressed that more patients and healthcare professionals around Australia would be able to take use of UroShield’s cutting-edge catheter care capabilities thanks to this renewed cooperation.

    Upcoming National Exposure and Clinical Engagement

    Dukehill will introduce UroShield at the 33rd National Conference on Incontinence, hosted by Continence Health Australia in Hobart in May 2025, in an effort to increase awareness and uptake even more. Clinicians from all around the nation will come together for the event, which will provide them a forum to talk about the study’s results and interact with the technology.

    The meeting is seen by NanoVibronix as a crucial chance to highlight UroShield’s therapeutic benefits and bolster its market share in Australia. NAOV seems to be well-positioned for further expansion in the healthcare technology industry due to its growing clinical relationships and growing worldwide awareness.

  • NanoVibronix (NAOV) Stock Surges In Pre-Market Trading Following A Positive Study

    NanoVibronix (NAOV) Stock Surges In Pre-Market Trading Following A Positive Study

    The share price of NanoVibronix, Inc. (NASDAQ: NAOV) increased significantly during pre-market trading, going up 79.82% to $3.92 as of the last check. The notable increase follows the publication of a successful independent study evaluating the company’s primary medical product, UroShield, by the Australian and New Zealand Continence Journal.

    An independent Validates UroShield’s Effectiveness

    The study highlights the device’s efficacy in reducing catheter-associated urinary tract infections (CAUTIs) and its potential for widespread clinical use among patients with indwelling urinary catheters (IUCs). UroShield customers showed encouraging outcomes from the independent health service research showing that Catheter blockages reduced by 70% while Catheter changes decreased by 52.3%.

    The positive impact of the device on patient care is further supported by the fact that clinicians saw less catheter-related interventions and more patient comfort. The study also discovered that UroShield decreased nursing effort and produced measurable cost savings for medical professionals.

    Better Patient Results and Cost Effectiveness

    The effectiveness of UroShield in a New Zealand District Nursing Service was described in depth in the published study, which also highlighted how it improves the quality of life for patients with IUCs. UroShield dramatically decreased catheter-associated infections and obstructions, resulting in fewer medical interventions and improved patient comfort, according to the Quality Improvement initiative.

    Furthermore, during a five-month period, the final cost analysis showed a 63.5% drop in resource consumption, mostly as a result of fewer medical interventions and emergency call-outs.

    Devices of the Future in Development

    Along with the encouraging trial findings, NanoVibronix recently reported that the design process for its next PainShield and UroShield devices was finished. In December 2024, a third-party contractor completed the creation of the prototype with an emphasis on lowering assembly costs, minimizing risk factors, and improving user ease.

    These advancements show NanoVibronix’s continuous efforts towards innovation in medical technology and supporting its prospects for further market expansion and acceptance. With these developments, NAOV is securing its position in the healthcare sector by offering innovative solutions to improve patient care and operational efficacy.

  • NAOV stock has plunged in the after-hours; Find out why

    NanoVibronix Inc. (NAOV) has plunged -7.07% at $0.79 in after-market trading hours on the last check Thursday. The NAOV stock lost -10.52% to complete the last trading session at $0.85. The price range of the NAOV stock was between $0.8324 and $0.931

    How NanoVibronix differentiates its medical devices

    NanoVibronix Inc. is a medical device company that specifically focuses on the manufacturing and sale of biological response-activating device that target would recovery, pain treatment, and biofilm prevention – all done noninvasively. The NAOV stock has a research and development team in Nesher, Israel that designs medical devices using its low-intensity surface acoustic wave which is proprietary and patented. NanoVibronix sells its product directly to clients and patients along with Federaly supply agreements with the United States. Similar distributor agreements are also made with India, Israel, Europe, and other international linkages.

    The SAW technology of the company is diversified due to its low-frequency ultrasound waves for medical applications which include bacterial colonization, biofilm disruption, and pain relief.  The leading products of the company include PainShield®, UroShield®, and WoundShieldTM.

    NAOV has secured another Federal Supply Schedule deal with VA

    On 2nd March 2021, NanoVibronix Inc. (NASDAQ: NAOV) announced that it entered into another Federal Supply Schedule agreement for its UroShield urology therapy device through a service-disabled veteran organization. This supply will be ordered through the Veterans Administration (VA) to make it easier to treat veterans with UroShield.

    The NAOV stock sells its medical devices directly but it also has a supply chain agreement with governmental contracts, particularly the Federal Supply Schedule in the USA. The FSS program is managed through a contract with the General Services Administration (GSA) which provides Federal agencies a more efficient and convenient process for procuring the commercial supplies in bulk for discounts. NAOV’s PainShield – a non-opioid pain therapy was also placed on FSS by the Veterans Administration on 1st September 2019.

    The veterans use Foley catheters which have a risk of catching Catheter-Associated Urinary Tract Infection (CAUTI) which is the leading cause of secondary hospital-acquired bloodstream infection. 40 million Americans undergo Urinary Catheterization, with 0.5 million CAUTI cases and 8000 deaths related to infection, every year.

    This is the market where UroShield is really differentiated and effective because it is attached to any indwelling urinary catheter as a disposable ultrasound device which reduces biofilm and prevents CAUTI. The ultrasound low intensity waves disrupt the docking mechanism of Bacteria and prevent bacterial colonization. UroShield is also effective against preventing hospitalization – a necessary action during the COVID-19 pandemic where hospitals focus on prioritizing hospital beds for COVID patients.

    NAOV is re-adjourning its Special Meeting of Stockholders again

    On 2nd March NAOV stock announced that its Special Meeting of Stockholders scheduled for 31st march, 2021 has been adjourned and rescheduled for 14th April 2021. This was done to allow more time for stockholders to vote.

    However on 14th April, the company announced again that the Special Meeting of Stockholders has been re-adjourned. It will now reconvene on 27th April 2021, at 10 am ET and virtually take place on the link here. NAOV will continue to solicit proxies from its stockholders and encourage them to vote before April 26, 20201 11:59 pm.